Correction: PARP1 inhibitor combined with oxaliplatin efficiently suppresses oxaliplatin resistance in gastric cancer-derived organoids via homologous recombination and the base excision repair pathway

There was a mistake in Figures 2, 4 as published. The wrong images were erroneously used for Figures 2G, 4A. The corrected Figures 2, 4 appear below.

FIGURE 2.

PARP1 is upregulated in oxaliplatin resistance gastric cancer. (G) Representative images of PARP1 levels stained by immunofluorescence in organoid and tumors. The scale bar represents 20 µm for tumour images, 200 µm for organoid images.

FIGURE 4.

PARP1 inhibition by Olaparib sensitizes gastric cancer to Oxaliplatin. (A–C) rGC1 organoids were treated with Olaparib + Oxaliplatin, Oxaliplatin, and Olaparib, respectively, before imaging (A), number of organoids (B), and size of organoids (C). The scale represents 500 µm.

The original version of this article has been updated.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.